Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

PURPOSE: The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the path...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Corless, Christopher L., Ballman, Karla V., Antonescu, Cristina R., Kolesnikova, Violetta, Maki, Robert G., Pisters, Peter W.T., Blackstein, Martin E., Blanke, Charles D., Demetri, George D., Heinrich, Michael C., von Mehren, Margaret, Patel, Shreyaskumar, McCarter, Martin D., Owzar, Kouros, DeMatteo, Ronald P.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2014
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4026579/
https://ncbi.nlm.nih.gov/pubmed/24638003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.2046
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares